UNITY Biotechnology

2023 was a pivotal year for UNITY.?? ? As we turn the page to 2024, we’re looking forward to continuing our mission to redefine the treatment paradigm for #DME. With many upcoming milestones, we’re thrilled to continue our momentum into the new year. Stay tuned for more to come!?? ? #UBX1325 #JPM24 #ReimagineAging?

Final call to register for our Ophthalmology Day event. TOMORROW – Don’t miss renowned #ophthalmology leaders’ presentations on our DME clinical program evaluating senolytic candidate #UBX1325, a live Q&A session and the opportunity to meet with the UNITY team on site in New York, NY. Can’t attend in-person? Virtual attendees can access the presentations online. Last chance to register: https://bit.ly/3XpnuCP

Today we recognize World Sight Day 2024 ????? ? At UNITY, we’re committed to advancing our senolytic candidate for retinal diseases. This #WorldSightDay, the theme “Love Your Eyes” reminds us how precious our sight is, emphasizing the importance of accessible treatments for those facing vision loss due to diseases like #DME. Today, we eagerly join the call to raise awareness, support breakthroughs in #ophthalmology, and make a lasting impact on global vision health for all. Learn more about our senolytic candidate #UBX1325 and register for our upcoming Ophthalmology Day for Investors and Analysts on October 15: https://bit.ly/3XpnuCP #WorldSightDay2024 #LoveYourEyes

Join us on October 15 for our Ophthalmology Day event —?available both virtually and in-person in New York, NY.? ? The event will feature key presentations from leading #ophthalmology experts and the UNITY management team, with a spotlight on the latest developments from our diabetic macular edema (DME) program. A live Q&A will follow the presentations, offering the opportunity to engage directly with our team. ? We look forward to seeing you there!? ? Register here:?https://bit.ly/3XpnuCP

Join UNITY Biotechnology (#UBX) on Tues, Oct. 15 at 8am ET in New York or virtually for its Ophthalmology Day for investors and analysts, featuring Robert Bhisitkul, MD, PhD (UCSF School of Medicine), Arshad Khanani, MD, MA, FASRS (Sierra Eye Associates, University of Nevada Reno School of Medicine), and Dante Pieramici, MD (California Retina Consultants). Register here: https://bit.ly/4gBf6rd

Save the date! Join us at our Ophthalmology Day for Investors and Analysts on October 15, 2024 in New York, NY.?? ? Our in-person and virtual event will feature presentations from prominent retina experts and members of the UNITY management team. We will focus on the latest data from our diabetic macular edema program and the ongoing Phase 2b ASPIRE study evaluating #UBX1325 head-to-head against aflibercept in DME. Additionally, a Q&A session will follow the formal presentations.?? ? See you there!?? ? Learn more details and register here: https://bit.ly/3ZEz66f

High blood sugar comes with a wide array of negative side effects. In diabetic patients, cellular senescence caused by sustained hyperglycemia damages the blood vessels in the retina – a key feature of #DME – and leads to vision loss. Our senolytic candidate #UBX1325 targets senescent cells in the retina, potentially reducing local inflammation and restoring vision in diabetic patients. Learn more: https://bit.ly/478Viac??

This Monday, our CEO Anirvan Ghosh, Ph.D. will provide a corporate update and company presentation at the H.C. Wainwright & Co., LLC 26th?Annual Global Investment Conference. Learn more and register for the live webcast:?https://bit.ly/4e0zGPz

Happy National Dog Day from UNITY Biotechnology!??? We're pawsitively thrilled to celebrate our favorite four-legged friends who bring endless joy, love, and a little bit of fur to our lives! Whether they're fetching their favorite toy or curling up by our feet during Zoom meetings, our canine companions are the ulti-mutt team members, always ready to lend a paw.??? ? Here's to the bark-tastic bond we share with our dogs— they're the real MVPs (Most Valuable Pups)!? ? #NationalDogDay #UltiMuttTeam

Our senolytic candidate UBX1325 is designed to enter the retina, eliminate senescent cells, and allow damaged tissue to heal itself. This disease-modifying approach could change the way we treat retinal diseases like #DME and potentially restore vision in patients.? ? Listen to Chief Scientist Mike (Przemyslaw) Sapieha, Ph.D. break down #UBX1325’s mechanism of action in DDN Dialogues’ podcast episode “Rejuvenating the retina to save vision” below and online here: https://bit.ly/3VBfCf7??